John Davis

Jennifer A. Woyach discusses congress insights from ASH 2024: https://lnkd.in/dSvEVgV4 In this interview she: • Summarizes BTK mutations and their impact on CLL treatment with BTKi • Adresses the impact of toxicity-related BTKi treatment discontinuation on the overall condition of CLL patients • Discusses combination therapy of BTK- and BCL-2 inhibitors in TN CLL patients The full memo inHaematology ASH 2024 SPECIAL ISSUE is coming soon! #ASH24 #Haematology #Hematology #CLL #Research

7

🎤 uBriGene Presents Exclusive Sessions at SAPA 2024 @Philly CGT Annual Conference 🎤 🚀 We're thrilled to announce our participation at 2024 @Philly Cell and Gene Therapy Annual Conference with two exclusive sessions aimed at revolutionizing the field: 1️⃣ An Innovative Technology for High Yield and More Stable #CRISPR Guide RNA: Discover how our innovative approach of using in vitro transcription (IVT) in producing guide RNA (#gRNA) that can simplify the process while being more cost-effective and free of organic chemicals. Join us to delve into the future of precision gene editing. 2️⃣ How Could CDMO and Technology Innovations Make CGT Affordable: Dive into the intersection #CDMO of and technological advancements with uBriGene. Learn about our strategies to drive down costs without compromising quality or efficacy. Let's explore how cutting-edge technology can make #CellandGeneTherapy more accessible to all. 2024 @Philly Cell and Gene Therapy Annual Conference brings together the innovators and business leaders to foster collaborations and advance cell and gene therapy in the #GreaterPhiladelphia area. 💡 Join #uBriGene to be at the forefront of innovation and collaboration in the dynamic world of cell and gene therapy and let's make cutting-edge cell and gene technology more accessible!

3

𝐀𝐥𝐧𝐲𝐥𝐚𝐦 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐑𝐞𝐯𝐞𝐚𝐥𝐬 𝐏𝐡𝐚𝐬𝐞 𝐈𝐈𝐈 𝐇𝐄𝐋𝐈𝐎𝐒-𝐁 𝐃𝐚𝐭𝐚 Alnylam Pharmaceuticals Alnylam Pharmaceuticals presented detailed data from the Phase III HELIOS-B study, showing that its RNA interference therapy, vutrisiran, may provide an additional survival benefit for transthyretin amyloidosis cardiomyopathy (ATTR-CM) patients already on Pfizer’s Vyndamax (tafamidis). The analysis at 42 months showed that vutrisiran, when added to Vyndamax, reduced all-cause mortality risk by 41% and lowered the composite endpoint of all-cause mortality and recurrent cardiovascular events by 22%. Although these results did not reach statistical significance, vutrisiran demonstrated a 36% reduction in all-cause mortality risk in the overall study population. Alnylam aims to file these results with regulators to make vutrisiran a new standard of care for ATTR-CM. These findings were presented at the 2024 Congress of the European Society of Cardiology and published in The New England Journal of Medicine. #Biotechnology #Cardiomyopathy #HELIOSB #RNAInterference #PharmaInnovation #TransthyretinAmyloidosis

1

Newco trend watch: Oligo delivery to the kidney, bispecifics for autoimmunity, and T cell engagers for intracellular tumor targets each get newcos, most with mega-raises

1

Learn how we collaborated with Checkpoint Therapeutics to develop a quantitative systems pharmacology model to support dose justification for anti-PD-L1 clinical candidate CK-301 in oncology patients. Read the case study at: https://lnkd.in/em3Dd3KH #oncology #drugdesign #drugdevelopment #mechanisticmodeling #qsp

18

Direct calcitonin gene-related peptide inhibition is associated with decreased rates of developing acne and rosacea compared with no inhibition (topiramate) or indirect inhibition (triptans) in patients experiencing migraines. https://ja.ma/4bCtlZ5

6

Can BTK inhibitors tackle cancer and autoimmunity? 🤔 💊 BTK inhibitors are a class of drugs that were initially developed to control the spread of cancer. Now, they are in the running to treat a host of autoimmune diseases.  Currently, Sanofi and Novartis’ drugs seem to be making progress in the clinic. 🏥 But that’s not to say that everything is going well in the field. These drugs have led to serious side effects in patients. 🤒 Read our latest article to find out more about these cancer drugs that are emerging as autoimmune therapies! 👇 https://lnkd.in/dqbBJ8nv #BTKinhibitors #cancertreatment #autoimmunetherapies #medicalresearch #drugdevelopment #healthcareadvancements InnoCare (HKEX: 09969; SSE: 688428) | Biogen | Merck | Gossamer Bio | Oncternal Therapeutics | Johnson & Johnson | AbbVie | Eli Lilly and Company | Loxo@Lilly | AstraZeneca | BeiGene

1

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial Ben Solomon Fabrice Barlesi Alice Shaw Walter Bordogna Roche American Society of Clinical Oncology (ASCO) https://lnkd.in/dQApcgWi #Cancer #Alectinib #ALINATrial #NSCLC #ClinicalTrial #DrugApproval #FDAApproved #JournalOfClinicalOncology #LungCancer #OncoDaily #Oncology

23

Nipocalimab, a mAb that blocks FcRn, was granted a Priority Review from the FDA. J&J has submitted Biologics License Application (BLA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) myasthenia gravis based on Phase 3 Vivacity-MG3 study.

25

Quantitative Systems Pharmacology (QSP) supports rare disease development Pompe disease is a rare and complex condition with severe infantile-onset (IOPD) and late-onset (LOPD) forms. To better understand treatment efficacy for IOPD patients, Sanofi’s team developed a quantitative systems pharmacology (QSP) "digital twin" model, leveraging Certara’s Virtual Twin technology. This innovative approach created virtual patient profiles to compare the effects of avalglucosidase alfa vs. the current standard of care. The findings highlight enhanced tissue glycogen clearance with avalglucosidase alfa, providing new insights into its mechanism of action and showcasing the power of digital twin technology in rare disease drug development.   Check out this recent publication by Sanofi, supported by Certara’s QSP Center of Excellence: https://ow.ly/7UMi50UtB2X #RareDisease #PompeDisease #VirtualTwinTechnology #QuantitativeSystemsPharmacology #DrugDevelopment #PrecisionMedicine

52

4 relevant business insights from ASCO: 1- Lilly revamped in oncology: would be enough to diversify portfolio 2-Need of multi regional clinical trials, specially when thinking in Chinese developments 3- Amgen KRAS treatment in CRC 4- ADCs fails in clinical trials and future development

3

In the Phase III ASC4FIRST trial, #SCEMBLIX was compared to investigator-selected TKIs, including GLEEVEC and second-generation TKIs. Patients received either 80 mg of SCEMBLIX once daily or an investigator-selected TKI at standard doses. The study met its primary endpoint, showing a major molecular response at 48 weeks of 67.7% for SCEMBLIX, compared to 49% for all investigator-selected TKIs. Although the increase in MMR with SCEMBLIX was not significantly higher than that with second-generation TKIs, 89.6% of SCEMBLIX-treated patients achieved early molecular responses by week 12, compared to 70.1% with investigator-selected TKIs. Additionally, 38% of patients treated with SCEMBLIX achieved deep molecular responses at 48 weeks, compared to 20.6% with investigator-selected TKIs. Unlock Invaluable Expert Insights and Thorough Analysis with DelveInsight Business Research LLP's European Hematology Association (EHA) 2024 Exclusive Coverage @ https://lnkd.in/gyCxcjcn #ASC4FIRST #PhaseIII #SCEMBLIX #TKI #GLEEVEC #CancerResearch #ClinicalTrials #MajorMolecularResponse #MMR #EarlyMolecularResponse #DeepMolecularResponse #Hematology #LeukemiaTreatment #MedicalResearch #Biotech #InnovativeTherapies #CancerTreatment #Oncology #HealthcareInnovation #ClinicalStudy #PharmaceuticalResearch

13

CRS3123 is a small molecule protein synthesis inhibitor that acts on the novel target methionyl-tRNA synthetase (MetRS). CRS3123 has numerous potential advantages over current CDI therapies.

4

Patients with psoriasis (PsO) and comorbid obesity may have a lower response to some biologics for PsO, compared to those without comorbid obesity. A pathological increase of adipose tissue contributes to a low-grade systemic inflammation and immune dysregulation which can extend to dermatological diseases such as psoriasis. To find out more visit: https://e.lilly/4hCi3Ir #PsoriasisAwareness #psoriasis #dermatology

4

#STORM is presenting 📢 interim Phase 1 data on its lead product, #STC15 at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024, entitled ‘𝙋𝘩𝙖𝙨𝙚 1 𝘿𝙤𝙨𝙚 𝙀𝙨𝙘𝙖𝙡𝙖𝙩𝙞𝙤𝙣 𝙖𝙣𝙙 𝘾𝙤𝘩𝙤𝙧𝙩 𝙀𝙭𝙥𝙖𝙣𝙨𝙞𝙤𝙣 𝙎𝙩𝙪𝙙𝙮 𝙀𝙫𝙖𝙡𝙪𝙖𝙩𝙞𝙣𝙜 𝙎𝙖𝙛𝙚𝙩𝙮, 𝙋𝙆, 𝙋𝘿 𝙖𝙣𝙙 𝘾𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝘼𝙘𝙩𝙞𝙫𝙞𝙩𝙮 𝙤𝙛 𝙎𝙏𝘾-15, 𝙖 𝙈𝙀𝙏𝙏𝙇3 𝙄𝙣𝘩𝙞𝙗𝙞𝙩𝙤𝙧, 𝙞𝙣 𝙋𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝙬𝙞𝙩𝘩 𝘼𝙙𝙫𝙖𝙣𝙘𝙚𝙙 𝙈𝙖𝙡𝙞𝙜𝙣𝙖𝙣𝙘𝙞𝙚𝙨 𝙬𝙤𝙧𝙡𝙙.’   The poster presentation will take place on June 1st from 9:00 - 12:00 CDT, and will focus on safety, pharmacokinetics, target modulation and clinical activity to support future clinical studies of STC-15.   𝙎𝙏𝘾-15 𝙞𝙨 𝙩𝘩𝙚 𝙛𝙞𝙧𝙨𝙩 𝙢𝙤𝙡𝙚𝙘𝙪𝙡𝙚 𝙨𝙥𝙚𝙘𝙞𝙛𝙞𝙘𝙖𝙡𝙡𝙮 𝙩𝙖𝙧𝙜𝙚𝙩𝙞𝙣𝙜 𝙖𝙣 𝙍𝙉𝘼 𝙢𝙚𝙩𝘩𝙮𝙡𝙩𝙧𝙖𝙣𝙨𝙛𝙚𝙧𝙖𝙨𝙚 𝙚𝙣𝙯𝙮𝙢𝙚 𝙩𝙤 𝙚𝙣𝙩𝙚𝙧 𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙙𝙚𝙫𝙚𝙡𝙤𝙥𝙢𝙚𝙣𝙩!   The ASCO Annual Meeting is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.   Learn more about #STORM and its ongoing Phase 1 clinical trial in the press release linked in the comments below!   #ASCO2024 #lifesciences #biotech #drugdiscovery #research #METTL3 #METTL1 #RNA

73

2 Comments

Fidar Rayka Pharmed: Bringing TrueNat Technology to Iran Fidar Rayka Pharmed is proud to be the exclusive representative of Molbio Diagnostics in Iran, introducing the cutting-edge TrueNat technology to Iran. Why TrueNat? - Point-of-Care Molecular Diagnostic Device: TrueNat is the point-of-care molecular diagnostic device approved by the World Health Organization (WHO). It is highly recommended for the swift and accurate diagnosis of tuberculosis (TB) and its drug resistance. - Endorsed by the World Health Organization (WHO) Since 2020, TrueNat has been recognized and endorsed by the WHO, featuring prominently in their 2024 guidelines as a primary solution for diagnosing TB and rifampicin resistance. - Transparent and Cost-Effective With installations in over 7,000 facilities across 80 countries, TrueNat has proven its cost-effectiveness and reliability, with no hidden fees. - Creation of Gene Biobank As the first point-of-care PCR device, TrueNat facilitates the creation of a gene biobank from extracted samples, paving the way for advanced genetic research. - Extensive Test Panel and Rapid Response TrueNat offers a comprehensive test panel with over 30 diagnostic options, including tests for dengue fever, high-risk human papillomavirus, rabies, Nipah virus, COVID-19, influenza A/B, hepatitis, malaria, and more. Its adaptability allows for the integration of new tests based on emerging health needs, ensuring quick and accurate results—often in under 40 minutes. - Durable Storage and Transportation TrueNat consumables are designed for resilience, with a shelf life of up to two years at 2-30°C and up to six months at 30-40°C. - Portable and Battery-Powered TrueNat’s portability and battery-powered operation make molecular diagnostics accessible anytime, anywhere. - Democratic and Decentralized Access TrueNat democratizes access to high-quality diagnostics, extending its reach to remote and underserved areas. - Seamless Connectivity and Data Transfer Equipped with Wi-Fi, GPRS, Bluetooth, and support for 3G, 4G, and 5G SIM cards, TrueNat ensures efficient data transfer to laboratory networks, enabling real-time monitoring of community health. #TrueNat #MolecularDiagnostics #HealthcareInnovation #PublicHealth #FidarRaykaPharmed #MolbioDiagnostics #IsfahanHealth #AdvancedTechnology #PointOfCare #DiseasePrevention #TBDiagnosis #GlobalHealth #MedicalInnovation #HealthTech #DiagnosticsSolutions

27

Excited to share the latest feature in our "Partnering Spotlight" series, where we share some of the connections we are building to foster scientific innovation in healthcare. In this edition, our very own Neha Kaushal sits down with Daniel Anderson, Professor of Chemical Engineering at MIT, to discuss the potential of innovative #mRNA applications in vaccines and novel treatments for genetic diseases. Check out the video to learn more about our collaboration! https://lnkd.in/eHwpyjeY #vaccines #immunoscience

40

1 Comment